Sandoz (SIX:SDZ / OTCQX:SDZNY), the global leader in affordable medicines, announced it will host a capital markets day for investors and analysts on Tuesday, September 8, 2026, at the London Stock Exchange. The event, titled 'Maximising Sandoz Value in Its Golden Decade for Biosimilars,' will run from 13:30 to 17:00 UK time and will be available via live webcast. In-person attendance is by invitation only on a first-come, first-served basis.
The formal part of the event will begin at 13:30 and will be webcast live. Details on accessing the webcast are available at the company's investor relations page. The capital markets day is expected to provide insights into Sandoz's strategy to leverage its position in the biosimilars market, which the company describes as entering a 'golden decade.'
In addition, Sandoz plans to host an investor and analyst site visit in Slovenia from November 9-10, 2026, offering deeper insight into its new biosimilars development and supply-chain hub. Attendance for this event will also be by invitation only on a first-come, first-served basis, and it will not be webcast.
This announcement comes as Sandoz celebrates 20 years of pioneering biosimilars in 2026, along with 80 years of antibiotics manufacturing and 140 years of heritage. The company reported net sales of USD 11.1 billion in 2025. With a portfolio of approximately 1,300 medicines and a global workforce of over 20,000 colleagues, Sandoz reaches more than one billion patients, generating substantial healthcare savings.
The capital markets day is significant for investors and the broader pharmaceutical industry as it underscores the growing importance of biosimilars in reducing healthcare costs and improving patient access. Biosimilars are biologic medical products highly similar to already approved reference biologics, offering more affordable treatment options. Sandoz's focus on this segment highlights the potential for growth and value creation in the coming decade.
For investors, the event will likely provide updates on pipeline developments, market expansion, and financial targets. The site visit to Slovenia further emphasizes Sandoz's commitment to building advanced manufacturing capabilities for biosimilars, which could enhance supply chain resilience and innovation.
The forward-looking statements in the release caution that actual results may differ due to risks including global economic conditions, exchange rates, legal provisions, market conditions, and competitor activities. Sandoz undertakes no obligation to publicly revise any forward-looking statements except as required by law.
For more information, investors and analysts can access the live webcast via the link provided on the Sandoz website. The company's global media relations and investor relations contacts are available for inquiries.
